• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒-细胞融合的温度阻滞中间体是HIV感染中的一个功能步骤。

The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection.

作者信息

Henderson Hamani I, Hope Thomas J

机构信息

University of Illinois @ Chicago, Department of Microbiology and Immunology, Chicago, IL 60612, USA.

出版信息

Virol J. 2006 May 25;3:36. doi: 10.1186/1743-422X-3-36.

DOI:10.1186/1743-422X-3-36
PMID:16725045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1482684/
Abstract

HIV entry occurs via membrane-mediated fusion of virus and target cells. Interactions between gp120 and cellular co-receptors lead to both the formation of fusion pores and release of the HIV genome into target cells. Studies using cell-cell fusion assays have demonstrated that a temperature-arrested state (TAS) can generate a stable intermediate in fusion related events. Other studies with MLV pseudotyped with HIV envelope also found that a temperature sensitive intermediate could be generated as revealed by the loss of a fluorescently labeled membrane. However, such an intermediate has never been analyzed in the context of virus infection. Therefore, we used virus-cell infection with replication competent HIV to gain insights into virus-cell fusion. We find that the TAS is an intermediate in the process culminating in the HIV infection of a target cell. In the virion-cell TAS, CD4 has been engaged, the heptad repeats of gp41 are exposed and the complex is kinetically predisposed to interact with coreceptor to complete the fusion event leading to infection.

摘要

HIV通过病毒与靶细胞的膜介导融合进入细胞。gp120与细胞共受体之间的相互作用导致融合孔的形成以及HIV基因组释放到靶细胞中。使用细胞-细胞融合试验的研究表明,温度阻滞状态(TAS)可在融合相关事件中产生稳定的中间体。其他用HIV包膜假型化的MLV进行的研究也发现,如通过荧光标记膜的丢失所揭示的那样,可产生温度敏感中间体。然而,从未在病毒感染的背景下分析过这种中间体。因此,我们使用具有复制能力的HIV进行病毒-细胞感染,以深入了解病毒-细胞融合。我们发现TAS是最终导致HIV感染靶细胞过程中的一个中间体。在病毒体-细胞TAS中,CD4已结合,gp41的七肽重复序列暴露,并且该复合物在动力学上易于与共受体相互作用以完成导致感染的融合事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/a1f9be5081cf/1743-422X-3-36-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/ad5c591cd46c/1743-422X-3-36-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/2f9d39aedab3/1743-422X-3-36-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/3ac187a3ccfc/1743-422X-3-36-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/a1f9be5081cf/1743-422X-3-36-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/ad5c591cd46c/1743-422X-3-36-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/2f9d39aedab3/1743-422X-3-36-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/3ac187a3ccfc/1743-422X-3-36-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfe2/1482684/a1f9be5081cf/1743-422X-3-36-4.jpg

相似文献

1
The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection.病毒-细胞融合的温度阻滞中间体是HIV感染中的一个功能步骤。
Virol J. 2006 May 25;3:36. doi: 10.1186/1743-422X-3-36.
2
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.酪氨酸硫酸化肽可逆且高效地激活 HIV-1 细胞进入,揭示了内吞进入和抑制剂作用机制。
J Virol. 2014 Apr;88(8):4304-18. doi: 10.1128/JVI.03447-13. Epub 2014 Jan 29.
3
Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.突变增加了 HIV-1 包膜糖蛋白 gp41 的融合后构象稳定性,被 X4 和 R5 HIV-1 病毒选择以逃避针对 gp41 七肽重复 1 的融合抑制剂,但两种病毒的 gp120 适应性突变不同。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.00142-19. Print 2019 Jun 1.
4
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.人类免疫缺陷病毒1型(HIV-1)对进入抑制剂的敏感性与包膜/共受体亲和力、受体密度及融合动力学相关。
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
5
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.对R5和X4病毒株具有广泛活性的HIV-1进入抑制剂的特性分析。
J Transl Med. 2015 Apr 2;13:107. doi: 10.1186/s12967-015-0461-9.
6
HIV entry inhibitors: mechanisms of action and resistance pathways.HIV进入抑制剂:作用机制与耐药途径
J Antimicrob Chemother. 2006 Apr;57(4):619-27. doi: 10.1093/jac/dkl027. Epub 2006 Feb 7.
7
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.HIV-1 gp41 融合中间态:HIV 治疗的一个靶点。
J Formos Med Assoc. 2010 Feb;109(2):94-105. doi: 10.1016/S0929-6646(10)60029-0.
8
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.动力学因素控制着人类免疫缺陷病毒的细胞进入效率、进入抑制剂的效力以及适应机制。
J Virol. 2005 Apr;79(7):4347-56. doi: 10.1128/JVI.79.7.4347-4356.2005.
9
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.1型人类免疫缺陷病毒对融合抑制剂T-20的敏感性受gp120 V3环所定义的共受体特异性调节。
J Virol. 2000 Sep;74(18):8358-67. doi: 10.1128/jvi.74.18.8358-8367.2000.
10
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.1型人类免疫缺陷病毒对靶向gp41第一个七肽重复序列的融合抑制剂的敏感性涉及gp41的不同区域,并始终受到gp120与共受体相互作用的调节。
J Virol. 2001 Sep;75(18):8605-14. doi: 10.1128/jvi.75.18.8605-8614.2001.

引用本文的文献

1
Replication differences of SARS-CoV-2 lineages may arise from unique RNA replication characteristics and nucleocapsid protein expression.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)谱系的复制差异可能源于独特的RNA复制特征和核衣壳蛋白表达。
Front Cell Infect Microbiol. 2025 Jul 11;15:1582137. doi: 10.3389/fcimb.2025.1582137. eCollection 2025.
2
Exploring the secrets of virus entry: the first respiratory syncytial virus carrying beta lactamase.探索病毒进入的奥秘:首例携带β-内酰胺酶的呼吸道合胞病毒
Front Microbiol. 2024 Feb 16;15:1339569. doi: 10.3389/fmicb.2024.1339569. eCollection 2024.
3
Structure dynamics of HIV-1 Env trimers on native virions engaged with living T cells.

本文引用的文献

1
Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane.HIV-1包膜糖蛋白介导的单个病毒粒子与细胞膜之间脂质和内含物混合的时间分辨成像。
Mol Biol Cell. 2005 Dec;16(12):5502-13. doi: 10.1091/mbc.e05-06-0496. Epub 2005 Sep 29.
2
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.人免疫缺陷病毒1型包膜蛋白(Env)、CD4和趋化因子受体的三元复合物形成,被捕获为膜融合的中间体。
J Virol. 2005 Sep;79(17):11161-9. doi: 10.1128/JVI.79.17.11161-11169.2005.
3
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.
HIV-1 Env 三聚体在与活 T 细胞结合的天然病毒上的结构动力学。
Commun Biol. 2021 Oct 27;4(1):1228. doi: 10.1038/s42003-021-02658-1.
4
Physicochemical tools for studying virus interactions with targeted cell membranes in a molecular and spatiotemporally resolved context.用于在分子水平和时空分辨率上研究病毒与靶向细胞膜相互作用的物理化学工具。
Anal Bioanal Chem. 2021 Dec;413(29):7157-7178. doi: 10.1007/s00216-021-03510-5. Epub 2021 Sep 7.
5
Cone-shaped HIV-1 capsids are transported through intact nuclear pores.锥形 HIV-1 衣壳通过完整的核孔运输。
Cell. 2021 Feb 18;184(4):1032-1046.e18. doi: 10.1016/j.cell.2021.01.025. Epub 2021 Feb 10.
6
Single-Molecule Super-Resolution Imaging of T-Cell Plasma Membrane CD4 Redistribution upon HIV-1 Binding.HIV-1 结合后 T 细胞质膜 CD4 再分布的单分子超分辨率成像
Viruses. 2021 Jan 19;13(1):142. doi: 10.3390/v13010142.
7
Analysis of CA Content and CPSF6 Dependence of Early HIV-1 Replication Complexes in SupT1-R5 Cells.分析 SupT1-R5 细胞中早期 HIV-1 复制复合物的 CA 含量和 CPSF6 依赖性。
mBio. 2019 Nov 5;10(6):e02501-19. doi: 10.1128/mBio.02501-19.
8
HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.HIV-1 锚定抑制剂和膜融合抑制剂针对病毒进入的不同但重叠的步骤。
J Biol Chem. 2019 Apr 12;294(15):5736-5746. doi: 10.1074/jbc.RA119.007360. Epub 2019 Jan 29.
9
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.创建人工尾部锚定物作为增强基于肽的HIV融合抑制剂效力的新策略。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01445-16. Print 2017 Jan 1.
10
Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone.甲基乙二醛双脒腙对巨噬细胞中HIV表达和整合的抑制作用
J Virol. 2015 Nov;89(22):11176-89. doi: 10.1128/JVI.01692-15. Epub 2015 Jul 29.
胞质尾部减缓了人类免疫缺陷病毒1型Env从晚期前聚体构型折叠成六螺旋束的过程。
J Virol. 2005 Jan;79(1):106-15. doi: 10.1128/JVI.79.1.106-115.2005.
4
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.靶向HIV-1 gp41 N端和C端螺旋区域的抑制剂揭示了HIV-1包膜糖蛋白介导融合过程中与温度相关的中间体。
Biochemistry. 2004 Jun 29;43(25):8230-3. doi: 10.1021/bi049957v.
5
The HIV Env-mediated fusion reaction.HIV包膜糖蛋白介导的融合反应。
Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50. doi: 10.1016/s0005-2736(03)00161-5.
6
Localization of CD4 and CCR5 in living cells.CD4和CCR5在活细胞中的定位。
J Virol. 2003 Apr;77(8):4985-91. doi: 10.1128/jvi.77.8.4985-4991.2003.
7
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.肽在两个位点捕获1型人类免疫缺陷病毒包膜糖蛋白融合中间体。
J Virol. 2003 Feb;77(3):1666-71. doi: 10.1128/jvi.77.3.1666-1671.2003.
8
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.人类免疫缺陷病毒1型(HIV-1)对进入抑制剂的敏感性与包膜/共受体亲和力、受体密度及融合动力学相关。
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
9
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.1型人类免疫缺陷病毒膜胆固醇在病毒内化中的作用。
J Virol. 2002 Oct;76(20):10356-64. doi: 10.1128/jvi.76.20.10356-10364.2002.
10
Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.1型人类免疫缺陷病毒利用脂筏共定位的CD4和趋化因子受体有效进入CD4(+) T细胞。
J Virol. 2002 May;76(10):4709-22. doi: 10.1128/jvi.76.10.4709-4722.2002.